Company: APM
Filing Date: 2025-10-14
Form Type: 424B5
Source: 0001213900-25-098635
Chunk: 7

Company: Aptorum Group Ltd
Filing Date: 2025-10-14
Form: 424B5
Chunk 7
---
 detection and monitoring of progression of glioblastoma until the earlier of the closing of the Merger or December 31, 2025.
In addition, concurrently with the execution of the Merger Agreement, DiamiR, DiamiR LLC, a wholly owned subsidiary of DiamiR, the Company,
and Aptorum Therapeutics entered into an intellectual property license agreement (“Licensing Agreement”), pursuant to which
DiamiR and DiamiR LLC shall license on a non-exclusive basis their respective intellectual properties to Aptorum Therapeutics in exchange
for upfront and periodic payments and royalties until the earlier of the closing of the Merger or December 31, 2025.

Immediately prior to the closing
of the Merger, we will transfer by way of continuation to and domesticate as a Delaware corporation (the “Domestication”;
the Company immediately following the Domestication and prior to the closing of Merger, “Aptorum Delaware”). In connection
with the Domestication, each of our then issued and outstanding Class A Ordinary Shares will convert automatically, on a one-for-one
basis, into a share of common stock of Aptorum Delaware, and each of our then issued and outstanding Class B ordinary shares will
convert automatically into a share of common stock of Aptorum Delaware and a share of non-voting and non-convertible Series A preferred
stock of Aptorum Delaware.

At the effective time of the
Merger (the “Effective Time”), each then-outstanding share of DiamiR’s common stock, other than dissenting shares, will
be converted into a number of shares of Aptorum Delaware common stock equal to the Conversion Ratio described in more detail in the section
titled “The Merger Agreement-Conversion Ratio” (the “Conversion Ratio”). Immediately following the closing of
the Merger, stockholders of DiamiR and our existing shareholders will own approximately 70% and 30%, respectively, of the outstanding
shares of the Combined Company.

DiamiR was incorporated in
Delaware on June 16, 2014, and primarily operates through its wholly owned subsidiary, DiamiR, LLC, which was incorporated as a limited
liability company in Delaware on September 17, 2009. DiamiR is a molecular diagnostics company focused on developing and commercializing
minimally invasive tests for early detection and monitoring of neurodegenerative diseases, such as mild cognitive impairment and Alzheimer’s
disease, rare neurodevelopmental diseases, such as Rett